Differences

This shows you the differences between two versions of the page.

--- documentation:oncology:meeting_notes_2019_jun-18 [2019/06/20 11:09] – created mgurley
+++ documentation:oncology:meeting_notes_2019_jun-18 [2019/06/20 11:16] (current) – mgurley
@@ Line 3: / Line 3: @@
 **Topics**
-* The group reviewed the following presentation:
-{{:documentation:oncology:ohdsi_oncology_meeting_06_11_2019.pdf| Presentation}}
-* The group discussed SQL showing how to map ICDO Site/Histology combinations to pre-coordinated Condition concepts.
-* The group discussed SQL showing how to find all Site/Histology combinations containing a particular ICDO site or histology.
+  * The group reviewed the following presentation: {{:documentation:oncology:ohdsi_oncology_meeting_06_18_2019.pdf| Presentation}}
-* It was announced that ICDO is currently already implemented within Athena and folks should try mapping their ICDO data.
+  * The group discussed the following questions:
-* The group discussed the plan to adopt NAACCR as OMOPS's standard vocabulary of cancer diagnosis modifiers and the plant to transition NAACCR from a standard vocabulary to source vocabulary by mapping NAACCR to the Nebraska Lexicon.
+  * Should representation of cancer staging within the OMOP vocabulary preserve the differences in possible values for cancer staging across anatomic site?  Or should the list of possible values be collapsed across anatomic sites?
+    * Group Consensus Answer: The list of possible values should be collapsed across anatomic sites.
-* Concern was expressed regarding the timeline for when the Nebraska Lexicon would be completed.
+  * Should representation of cancer staging within the OMOP vocabulary include system (AJCC vs. UICC vs others) and version? Or should the list of possible values be collapsed across systems and versions?
+    * Group Consensus Answer: The list of possible values be collapsed across systems and versions.
-* There was consensus in the group that the OMOP community needs to standardize the representation of cancer  diagnosis modifiers.  Some members of the group might take a swipe at recommending cancer diagnosis modifiers ahead of the Nebraska Lexicon completion date.
-* It was announced that the Hemonc.org drug regimen ontology has been released within Athena.
-* The group discussed the current state of the Hemonc.org vocabulary.  Regimens and regimen components mapped to RxNorm ingredients.  Plus a better drug oncology classification system.
-* The group asked about the future possibility of including regimen dosing, cycles and indications.  Dmytry informed the group that these items would be part of future releases.